Featured Research

from universities, journals, and other organizations

New Ovarian Cancer Hope For Women; Scientists Bring Early Detection Closer

Date:
June 25, 2003
Source:
Pacific Northwest Research Institute
Summary:
Scientists at the Pacific Northwest Research Institute (PNRI) in Seattle announced a new biomarker for ovarian cancer today. Their discovery promises improved diagnosis of the disease, which usually remains hidden until it is too late for effective treatment.

Seattle, WA -- Scientists at the Pacific Northwest Research Institute (PNRI) in Seattle announced a new biomarker for ovarian cancer today. Their discovery promises improved diagnosis of the disease, which usually remains hidden until it is too late for effective treatment.

In the July 1 issue of Cancer Research, the researchers describe a molecule, HE4, associated with ovarian cancer cells. Because the molecule is secreted readily into the blood, its presence should be detectable when simple and inexpensive clinical blood tests are developed.

"Many cancers have a high cure rate if diagnosed early," Dr. Ingegerd Hellstrom, a principal scientist at PNRI and the lead author of the new paper, says. "But not if diagnosed late. Unfortunately, ovarian carcinoma is most often diagnosed when it is already in an advanced stage. Even after surgery and chemotherapy, relapses are common."

According to the American Cancer Society, the survival statistics are dismal. Three out of four cases of ovarian cancer are diagnosed in late stages. Last year alone, nearly 14,000 women died of the disease.

The best currently available diagnostic test for ovarian cancer is CA125. It is useful in diagnosing late stage cancers, and in detecting the recurrence of tumors after chemotherapy and radiation. But it is not very effective in identifying early stage disease. It also sometimes indicates the presence of ovarian cancer where there is none. Such "false positive" results lead to dangerous, expensive, and unnecessary treatment.

In the Cancer Research study, the new biomarker, HE4, proved to be at least as effective as CA125. And where no false positive results occurred, HE4's sensitivity to ovarian carcinoma was 40% higher than that of CA125.

"I'm very anxious to do something for patients," Hellstrom says. But there is much work to be done, laboratory studies with larger numbers of serum samples, and commercial development to design effective clinical applications of the research. The possibility that a simple and inexpensive blood test can be developed for clinical use is already being studied in a licensing agreement with Fujirebio Diagnostics Incorporated, the creator of CA125.

"Still, this is a step in the right direction," Hellstrom says. "And we are working as passionately and creatively as we can, to curtail this terrible disease."


Story Source:

The above story is based on materials provided by Pacific Northwest Research Institute. Note: Materials may be edited for content and length.


Cite This Page:

Pacific Northwest Research Institute. "New Ovarian Cancer Hope For Women; Scientists Bring Early Detection Closer." ScienceDaily. ScienceDaily, 25 June 2003. <www.sciencedaily.com/releases/2003/06/030625085924.htm>.
Pacific Northwest Research Institute. (2003, June 25). New Ovarian Cancer Hope For Women; Scientists Bring Early Detection Closer. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2003/06/030625085924.htm
Pacific Northwest Research Institute. "New Ovarian Cancer Hope For Women; Scientists Bring Early Detection Closer." ScienceDaily. www.sciencedaily.com/releases/2003/06/030625085924.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins